Literature DB >> 26885293

Is postoperative nausea and vomiting still the big "little" problem?

Sung Uk Choi1.   

Abstract

Entities:  

Year:  2016        PMID: 26885293      PMCID: PMC4754258          DOI: 10.4097/kjae.2016.69.1.1

Source DB:  PubMed          Journal:  Korean J Anesthesiol        ISSN: 2005-6419


× No keyword cloud information.
Postoperative nausea and vomiting (PONV) is usually defined as any nausea, retching, or vomiting occurring within the first 24–48 hours of surgery. PONV can be extremely distressing to patients and is one of the most common causes of patient dissatisfaction and discomfort after anesthesia. The average incidence of PONV after general anesthesia is about 30% in all post-surgical patients but up to 80% in high-risk patients despite advances in anesthetics and anesthesia techniques [123]. In addition, PONV is rated highly in preoperative surveys, as the clinical anesthesia outcome that the patient would most like to avoid [4]. Therefore it is not surprising that patients express a high willingness-to-pay ($50–100) to avoid PONV [56]. While bleeding, wound dehiscence, pulmonary aspiration of gastric contents, esophageal perforation, and other serious complications associated with PONV are rare, nausea and vomiting is still an unpleasant, unwanted and all-too-common postoperative morbidity that can delay patient discharge from the postanesthesia care unit, require expanded levels of nursing care and increase unanticipated overnight hospital admissions in outpatients. The public now believes that anesthesia is extraordinarily safe from catastrophic outcomes, including major organ dysfunction or failure and even death. Therefore, many patients are more concerned about pain and PONV than surgical outcomes, such as whether the surgery would improve their condition. This is especially true for the majority of patients undergoing less invasive surgery. Moreover, minimally invasive surgery is now increasingly and routinely used across almost all surgical specializations. An important aspect of the quality of anesthetic care is the satisfaction of the patient with their care. Possible strategies to prevent the incidence of PONV include the prophylactic use of antiemetics such as dexamethasone or 5-HT3 antagonists, and avoiding use of emetic drugs such as inhalational anesthetics or opioids. However, no drug is completely effective at preventing PONV. If we can avoid drugs that cause PONV, all the better. The etiology of PONV remains unclear, but involves anesthetic, surgical and patient factors. Well-known risk factors are female gender, non-smoking status, a history of motion sickness or previous PONV, inhalational anesthetics, certain types of surgery, and opioid use [7]. Among the risk factors for PONV, the use of postoperative opioids is one of four major risk factors in the simplified risk-scoring system introduced by Apfel et al. [8]. In this month's Korean Journal of Anesthesiology, Lim et al. [9] report a study focusing on the effects of intraoperative opioid use on the incidence and severity of PONV and the effects of a single bolus administration of fentanyl during anesthesia induction versus intraoperative infusion of remifentanil on PONV. In a previous randomized controlled trial in over 5000 patients, the use of a short-acting opioid, like remifentanil, instead of fentanyl did not decrease the incidence of PONV [10]. However, in that study, patients who had been assigned to receive intraoperative remifentanil were given 50 µg of morphine per kilogram or an equivalent opioid at the end of surgery. Therefore, the current study has meaningful results based on comparing only fentanyl versus remifentanil itself, without the other factors that affect PONV. They demonstrated that a single bolus administration of fentanyl during anesthesia induction increased the incidence of PONV, while an intraoperative remifentanil infusion did not affect the incidence and severity of PONV. These results should have a marked synergistic effect with antiemetic prophylaxis. It should be kept in mind that even a single bolus administration of fentanyl during anesthesia induction can increase the incidence of PONV in high-risk patients.
  9 in total

1.  A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers.

Authors:  C C Apfel; E Läärä; M Koivuranta; C A Greim; N Roewer
Journal:  Anesthesiology       Date:  1999-09       Impact factor: 7.892

2.  Effect of postoperative experiences on willingness to pay to avoid postoperative pain, nausea, and vomiting.

Authors:  Jolanda E van den Bosch; Gouke J Bonsel; Karel G Moons; Cor J Kalkman
Journal:  Anesthesiology       Date:  2006-05       Impact factor: 7.892

3.  How much are patients willing to pay to avoid postoperative nausea and vomiting?

Authors:  T Gan; F Sloan; G de L Dear; H E El-Moalem; D A Lubarsky
Journal:  Anesth Analg       Date:  2001-02       Impact factor: 5.108

4.  Consensus guidelines for the management of postoperative nausea and vomiting.

Authors:  Tong J Gan; Pierre Diemunsch; Ashraf S Habib; Anthony Kovac; Peter Kranke; Tricia A Meyer; Mehernoor Watcha; Frances Chung; Shane Angus; Christian C Apfel; Sergio D Bergese; Keith A Candiotti; Matthew Tv Chan; Peter J Davis; Vallire D Hooper; Sandhya Lagoo-Deenadayalan; Paul Myles; Greg Nezat; Beverly K Philip; Martin R Tramèr
Journal:  Anesth Analg       Date:  2014-01       Impact factor: 5.108

5.  Can postoperative nausea and vomiting be predicted?

Authors:  D R Sinclair; F Chung; G Mezei
Journal:  Anesthesiology       Date:  1999-07       Impact factor: 7.892

6.  A survey of postoperative nausea and vomiting.

Authors:  M Koivuranta; E Läärä; L Snåre; S Alahuhta
Journal:  Anaesthesia       Date:  1997-05       Impact factor: 6.955

7.  Which clinical anesthesia outcomes are important to avoid? The perspective of patients.

Authors:  A Macario; M Weinger; S Carney; A Kim
Journal:  Anesth Analg       Date:  1999-09       Impact factor: 5.108

8.  A factorial trial of six interventions for the prevention of postoperative nausea and vomiting.

Authors:  Christian C Apfel; Kari Korttila; Mona Abdalla; Heinz Kerger; Alparslan Turan; Ina Vedder; Carmen Zernak; Klaus Danner; Ritva Jokela; Stuart J Pocock; Stefan Trenkler; Markus Kredel; Andreas Biedler; Daniel I Sessler; Norbert Roewer
Journal:  N Engl J Med       Date:  2004-06-10       Impact factor: 91.245

9.  The postoperative interview: assessing risk factors for nausea and vomiting.

Authors:  M M Cohen; P G Duncan; D P DeBoer; W A Tweed
Journal:  Anesth Analg       Date:  1994-01       Impact factor: 5.108

  9 in total
  4 in total

1.  Study protocol for a randomised, patient- and observer-blinded evaluation of P6 acustimulation for the prevention of nausea and vomiting in the postoperative period in patients receiving routine pharmacological prophylaxis (P6NV-Trial).

Authors:  Benedict Weber; Selena Knoth; Peter Kranke; Leopold Eberhart
Journal:  Trials       Date:  2022-06-16       Impact factor: 2.728

2.  Dexamethasone alone versus in combination with intra-operative super-hydration for postoperative nausea and vomiting prophylaxis in female patients undergoing laparoscopic cholecystectomy: a randomized clinical trial.

Authors:  Eman A Ismail; Mohamed H Bakri; Sayed Kaoud Abd-Elshafy
Journal:  Korean J Anesthesiol       Date:  2017-05-19

3.  The role of platelet count, mean platelet volume, and the mean platelet volume/platelet count ratio in predicting postoperative vomiting in children after deep sedation.

Authors:  Dilek G Canpolat; Fatma Dogruel; Zeynep B Gönen; Canay Yılmaz; Gokmen Zararsız; Alper Alkan
Journal:  Saudi Med J       Date:  2016-10       Impact factor: 1.484

4.  Comparison of palonosetron and dexamethasone with ondansetron and dexamethasone for postoperative nausea and vomiting in postchemotherapy ovarian cancer surgeries requiring opioid-based patient-controlled analgesia: A randomised, double-blind, active controlled study.

Authors:  Amit Kumar; Sohan Lal Solanki; Gauri Raman Gangakhedkar; T S Shylasree; Kailash S Sharma
Journal:  Indian J Anaesth       Date:  2018-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.